BENEFIT-RISK ANALYSIS OF ADALIMUMAB AND ALTERNATIVE TREATMENTS FOR MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS

被引：0
|
作者：
Hicks, K. A. [1 ]
Earnshaw, S. R. [1 ]
Shaw, J. W. [2 ]
Cifaldi, M. [2 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1360
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A439 / A440
页数：2
相关论文
共 50 条
  • [31] Letter to the editor concerning the article: "Comparative safety and benefit-risk profile of biologics and oral treatments for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data"
    Pettitt, Dan
    Plotnick, Michael
    Miller, Lloyd S.
    Berlin, Jesse A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (05) : E305 - E306
  • [32] Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis
    Chongqing Tan
    Xia Luo
    Sini Li
    Lidan Yi
    Xiaohui Zeng
    Liubao Peng
    Shuxia Qin
    Liting Wang
    Xiaomin Wan
    Clinical Rheumatology, 2022, 41 : 63 - 73
  • [33] Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden
    Bansback, NJ
    Brennan, A
    Ghatnekar, O
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) : 995 - 1002
  • [34] Sequences of biological treatments for patients with moderate-to-severe rheumatoid arthritis in the era of treat-to-target in China: a cost-effectiveness analysis
    Tan, Chongqing
    Luo, Xia
    Li, Sini
    Yi, Lidan
    Zeng, Xiaohui
    Peng, Liubao
    Qin, Shuxia
    Wang, Liting
    Wan, Xiaomin
    CLINICAL RHEUMATOLOGY, 2022, 41 (01) : 63 - 73
  • [35] BUDGET IMPACT ANALYSIS OF BARICITINIB FOR THE MANAGEMENT OF MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS IN THE KINGDOM OF SAUDI ARABIA
    Almodaimegh, H.
    Alrumaih, A.
    Alabdulkarim, H. A. A.
    Alsaqa'aby, M.
    Alturaiki, A.
    Erdogan, A.
    Alhowimel, M.
    Alhammad, A.
    El Ojeil, R.
    Biswas, C.
    VALUE IN HEALTH, 2020, 23 : S412 - S412
  • [36] Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis
    Janet Pope
    Ruta Sawant
    Namita Tundia
    Ella X. Du
    Cynthia Z. Qi
    Yan Song
    Patrick Tang
    Keith A. Betts
    Advances in Therapy, 2020, 37 : 2356 - 2372
  • [37] Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis
    Pope, Janet
    Sawant, Ruta
    Tundia, Namita
    Du, Ella X.
    Qi, Cynthia Z.
    Song, Yan
    Tang, Patrick
    Betts, Keith A.
    ADVANCES IN THERAPY, 2020, 37 (05) : 2356 - 2372
  • [38] Economic Evaluation of Sequences of Biological Treatments for Patients With Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Methotrexate in France
    Ghabri, Salah
    Binard, Aymeric
    Pers, Yves-Marie
    Maunoury, Franck
    Caro, J. Jaime
    VALUE IN HEALTH, 2020, 23 (04) : 461 - 470
  • [39] Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program
    Conaghan, Philip G.
    Mysler, Eduardo
    Tanaka, Yoshiya
    Da Silva-Tillmann, Barbara
    Shaw, Tim
    Liu, John
    Ferguson, Ryan
    Enejosa, Jeffrey V.
    Cohen, Stanley
    Nash, Peter
    Rigby, William
    Burmester, Gerd
    DRUG SAFETY, 2021, 44 (05) : 515 - 530
  • [40] Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data
    Shear, Neil H.
    Betts, Keith A.
    Soliman, Ahmed M.
    Joshi, Avani
    Wang, Yan
    Zhao, Jing
    Gisondi, Paolo
    Sinvhal, Ranjeeta
    Armstrong, April W.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : 572 - 581
12345